Obesity drug developers rise as Metsera receives fresh bid from Novo Nordisk

Metsera

30/10/2025 16:07

Updates

** Shares of obesity drug developer Metsera MTSR.O jump 24.4% to a record high of $64.93

** Novo Nordisk NOVOb.CO proposes $6.5 bln deal for Metsera, including debt, with an additional $2.5 billion in milestone-based payments via CVRs

** Shares of other obesity drug developers Viking Therapeutics VKTX.O rise 10.6%, Altimmune ALT.O climb 4.8%, Structure Therapeutics GPCR.O up 5.8% at $31.29

** Last month, Pfizer PFE.N said it would acquire Metsera in a deal valued at up to $7.3 billion, including future payments

** Metsera develops early and mid-stage drugs for obesity and diabetes

** U.S.-listed shares of Novo Nordisk NOVOb.CO down 2.3%

** "Novo's competitive bid continues to show that large Pharma has an interest in buying into obesity (even if they are already established with commercial assets) in order to capitalize on the significant market opportunity," brokerage BMO Capital Markets says

** Including sessions move, MTSR up 97.01% since debut in January

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))